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Introduction
Arsenic (As) is a class I human carcinogen that 
causes several types of cancer (International 
Agency for Research on Cancer 2004). 
Chronic As exposure through contami-
nated drinking water has also been linked to 
increased mortality (Argos et al. 2010) and 
both coronary (Chen et al. 2011; States et al. 
2009) and respiratory diseases (Parvez et al. 
2008, 2010). Approximately 140 million 
people worldwide are chronically exposed to 
As-contaminated drinking water at concentra-
tions > 10 µg/L; > 57 million of these exposed 
individuals live in Bangladesh (Kinniburgh 
and Smedley 2001; World Bank 2005). 
Inorganic As (InAs) undergoes methyla-
tion via nutrient-dependent one-carbon 
metabolism, first to mono methyl arsonic acid 
(MMAsV), and then to dimethyl arsinic acid 
(DMAsV) (Figure 1). Arsenic metabolites dif-
fer in toxicity, and individuals vary in their 
ability to methylate InAs. Epidemiologic 
studies have shown that a lower capacity to 
methylate InAs to DMAV, based on rela-
tive amounts of As metabolites in urine, is 
positively associated with risk for several 
diseases (Steinmaus et al. 2010). The precise 
mechanisms through which As causes disease 
are poorly understood, although oxidative 
stress (defined as an imbalance between anti-
oxidant defense and the total burden of poten-
tially harmful reactive biochemical species) 
is often cited as a likely mechanism (Jomova 
et al. 2011).
Glutathione (GSH), a tripeptide con-
sisting of cysteine (Cys), glutamic acid, 
and glycine, is a critical component of the 
body’s primary anti oxidant defense mecha-
nism (Forman et al. 2009). GSH also serves 
as the electron donor for the reduction of 
arsenate (AsV) to arsenite (AsIII) (Scott et al. 
1993). GSH can detoxify reactive oxygen spe-
cies (ROS) directly and is also a substrate 
for glutathione peroxidase, a seleno protein 
that enzymatically reduces hydrogen per-
oxide and lipid hydro peroxides (Lu 2009). 
Detoxification of ROS produces the oxidized 
metabo lite glutathione disulfide (GSSG), 
which can be reduced back to GSH through 
the action of glutathione reductase. Another 
critical function of GSH is to provide a reser-
voir of Cys in order to maintain overall sulfur 
amino acid balance (Figure 1). Cells can tol-
erate only low concentrations of Cys, which 
is unstable and rapidly oxidizes to cystine 
(CySS), producing potentially toxic oxygen 
free radicals (Lu 2009).
A decrease in GSH and increase in GSSG 
is indicative of chronic oxidative stress, 
and severe oxidative stress has been shown 
to deplete GSH (Lu 1999). Furthermore, 
changes in the reduction potential (Eh) 
of the GSH/GSSG and Cys/CySS thiol/
disulfide pairs may influence redox-sensitive 
signaling pathways and enzymes (Jones 2002). 
Concentrations of reduced and oxidized 
forms of a paired redox couple can be used 
to estimate the redox state (in milli volts) with 
the Nernst equation (Jones et al. 2002). The 
GSH/GSSG thiol/disulfide redox couple 
maintains a highly reduced intra cellular state 
that controls cell cycle progression and intra-
cellular anti oxidant defenses (Schafer and 
Buettner 2001). In plasma, Cys and CySS 
are present at much higher concentrations 
than GSH and GSSG, and are thus the 
primary determinants of the extra cellular 
redox state (Jones et al. 2002). The high intra-
cellular (1–10 mM) and lower extra cellular 
(1–10 µM) concentrations of GSH might 
render extra cellular surfaces more vulnerable 
to oxida tive damage (Lu 2009; Smith et al. 
1996); this may be partially counter acted by 
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Background: In vitro and rodent studies have shown that arsenic (As) exposure can deplete 
 glutathione (GSH) and induce oxidative stress. GSH is the primary intra cellular anti oxidant; 
it donates an electron to reactive oxygen species, thus producing glutathione disulfide (GSSG). 
Cysteine (Cys) and cystine (CySS) are the predominant thiol/disulfide redox couple found in 
human plasma. Arsenic, GSH, and Cys are linked in several ways: a) GSH is synthesized via the 
trans sulfuration pathway, and Cys is the rate-limiting substrate; b) intermediates of the methionine 
cycle regulate both the trans sulfuration pathway and As methylation; c) GSH serves as the electron 
donor for reduction of arsenate to arsenite; and d) As has a high affinity for sulfhydryl groups and 
therefore binds to GSH and Cys.
oBjectives: We tested the hypothesis that As exposure is associated with decreases in GSH and Cys 
and increases in GSSG and CySS (i.e., a more oxidized environment).
Methods: For this cross-sectional study, the Folate and Oxidative Stress Study, we recruited a 
total of 378 participants from each of five water As concentration categories: < 10 (n = 76), 10–100 
(n = 104), 101–200 (n = 86), 201–300 (n = 67), and > 300 µg/L (n = 45). Concentrations of GSH, 
GSSG, Cys, and CySS were measured using HPLC.
results: An interquartile range (IQR) increase in water As was negatively associated with blood 
GSH (mean change, –25.4 µmol/L; 95% CI: –45.3, –5.31) and plasma CySS (mean change, 
–3.00 µmol/L; 95% CI: –4.61, –1.40). We observed similar associations with urine and blood As. 
There were no significant associations between As exposure and blood GSSG or plasma Cys.
conclusions: The observed associations are consistent with the hypothesis that As may influence 
concentrations of GSH and other non protein sulfhydryls through binding and irreversible loss in 
bile and/or possibly in urine.
citation: Hall MN, Niedzwiecki M, Liu X, Harper KN, Alam S, Slavkovich V, Ilievski V, Levy D, 
Siddique AB, Parvez F, Mey JL, van Geen A, Graziano J, Gamble MV. 2013. Chronic arsenic expo-
sure and blood glutathione and glutathione disulfide concentrations in Bangladeshi adults. Environ 
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the high extra cellular concentrations of the 
Cys/CySS redox pair.
One-carbon metabolism is the biochemi-
cal pathway through which As and numerous 
other substrates are methylated (Figure 1). A 
portion of homo cysteine generated through 
one-carbon metabolism is remethylated to 
form methionine, which is then activated to 
form the methyl donor, S-adenosyl methio-
nine (SAM). Alternatively, homo cysteine can 
be directed to the trans sulfuration pathway 
and used in the synthesis of GSH (Figure 1). 
Under conditions of oxidative stress, the shunt-
ing of homo cysteine to the trans sulfuration 
pathway is increased through the up-regulation 
of the GSH biosynthetic enzymes, including 
γ-glutamate-cysteine ligase (GCL), the rate-
limiting enzyme of GSH synthesis (Lu 2009). 
Although most cell types can synthesize GSH, 
the liver is the major site of synthesis.
There are several mechanisms through 
which As may influence concentrations of 
GSH and GSSG, including a) inducing the 
formation of ROS, which are then detoxi-
fied by GSH; b) consuming GSH during the 
reduction of AsV to AsIII (Scott et al. 1993); 
c) forming As/GSH complexes, which are 
substrates for the ATP-binding cassette mem-
brane transporters that mediate efflux from 
cells (Leslie et al. 2004; Thomas 2009); and 
d) inhibiting glutathione reductase, thereby 
limiting the regeneration of GSH from GSSG 
(Massey and Williams 1965; Styblo et al. 
1997; Styblo and Thomas 1995). In vitro 
and animal studies have shown that As can 
deplete GSH (Santra et al. 2000). Thus, the 
depletion of GSH may be one mechanism 
through which As could lead to oxidative 
stress. However, given the well-known species 
differences in As metabolism and susceptibil-
ity to As-induced health effects (Drobná et al. 
2010), additional data derived from human 
population studies are needed.
We conducted a cross-sectional study of 
378 Bangladeshi adults to test the primary 
hypothesis that chronic As exposure is associ-
ated with reductions in GSH and increases 
in GSSG. We also wished to test the second-
ary hypothesis that chronic As exposure is 
associated with reductions in plasma Cys and 
increases in CySS.
Subjects and Methods
Participants and procedures. Participants in 
the current study, the Folate and Oxidative 
Stress (FOX) Study, were recruited between 
February and July of 2008 in Araihazar, 
Bangladesh. Potential participants were identi-
fied on the basis of well water As (wAs) con-
centrations obtained from a well survey in the 
year 2000 (van Geen et al. 2002) in order to 
ensure a wide range of As exposures for the 
examination of dose-dependent relationships. 
A new water sample was collected at the time 
of enrollment for analysis of wAs concentra-
tion. Individuals were eligible to participate in 
FOX if they a) were between 30 and 65 years 
of age; b) were not pregnant; c) were not tak-
ing nutritional supplements; d) did not have 
known diabetes, cardio vascular or renal dis-
ease, chronic obstructive pulmonary disease, 
or cancer; and e) had been drinking water 
from their current well for at least 3 months. 
Trained recruiters identified eligible par-
ticipants, explained the nature of the study, 
obtained informed consent, and scheduled 
a field clinic visit. Because GSH is unstable 
and therefore requires that blood samples be 
processed immediately, all visits were con-
ducted in the laboratory at our field clinic 
in Araihazar. During the field clinic visit, a 
trained interviewer adminis tered a detailed 
questionnaire to each participant, and a physi-
cian collected a venous blood sample. Urine 
samples were collected in 50-mL acid-washed 
poly propylene tubes and frozen at –20°C.
The primary aim of this study was to 
examine the dose–response relationship 
between As exposure and measures of oxida-
tive stress. We aimed to recruit 75 partici pants 
each from five wAs concentration cate-
gories: < 10, 10–100, 101–200, 201–300, 
and > 300 µg/L. However, the final sample 
included more partic pants with lower expo-
sures because many households switched to 
lower-As wells after wells in the region were 
surveyed for As in 1999–2000 (Chen et al. 
2007). Therefore, the final distribution 
among well wAs exposure cate gories was 
< 10 µg/L (n = 76), 10–100 µg/L (n = 104), 
101–200 µg/L (n = 86), 201–300 µg/L 
(n = 67), and > 300 µg/L (n = 45).
Oral informed consent was obtained by 
our Bangladeshi field staff physicians, who 
read an approved assent form to the study 
participants. This study was approved by the 
Bangladesh Medical Research Council and 
the institutional review board of Columbia 
University Medical Center.
Sample collection and handling. After 
the initial processing of blood samples in the 
field clinic, the blood and plasma aliquots 
were immediately frozen at –80°C. Samples 
on dry ice were transported in batches to 
Dhaka, Bangladesh, by car and again stored at 
–80°C (blood and plasma) or –20°C (urine). 
Figure 1. One-carbon metabolism and glutathione (GSH) synthesis and metabolism. Abbreviations: B12, 
vitamin B12; BHMT, betaine homocysteine methyltransferase; DMA, dimethyl arsinic acid; InAs, inorganic 
As; MMA, mono methyl arsonic acid. Folic acid is reduced to tetra hydrofolate (THF) and subsequently 
converted to 5-methyl THF. In a reaction catalyzed by methionine synthetase (MTR), the methyl group 
of 5-methyl-THF can be transferred to homocysteine, generating methionine. Methionine is activated to 
form S-adenosylmethionine (SAM), the universal methyl donor. The by-product of methyla tion reactions, 
S-adenosyl homocysteine (SAH), is hydrolyzed to homocysteine. Homocysteine is either used to regenerate 
methionine or is directed to the trans sulfuration pathway. GSH is a product of the transsulfuration pathway. 
GSH can serve as a continuous source of cysteine, which is extremely unstable, via the γ-glutamyl cycle 
(adapted from Lu 2009). GSH is exported from the cell, and the enzyme γ-glutamyltransferase (GGT) trans-
fers the γ-glutamyl moiety of GSH to an amino acid, often cystine, producing cysteinylglycine and γ-glutamyl 
amino acid. The γ-glutamyl amino acid can be transported back into the cell and ultimately metabolized to 
glutamate. Cysteinylglycine is converted to cysteine and glycine by dipeptidase (DP). Cysteine is unstable 
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Samples were then packed on dry ice in 
coolers and transported by air to Columbia 
University.
wAs. Field sample collection and labora-
tory analysis procedures have been previ-
ously described in detail (Cheng et al. 2004; 
van Geen et al. 2005). Water samples were 
collected in 20-mL polyethylene scintillation 
vials. The samples were acidified to 1% with 
high-purity Optima HCl (Fisher Scientific, 
Pittsburg, PA, USA) at least 48 hr before 
analysis (van Geen et al. 2007). Water samples 
were analyzed by high-resolution inductively 
coupled plasma mass spectrometry (ICP-MS) 
after 1:10 dilution and addition of a germa-
nium spike to correct fluctuations in instru-
ment sensitivity. The detection limit of the 
method is typically < 0.2 µg/L (Cheng et al. 
2004). A standard with an As concentration of 
51 µg/L was run multiple times in each batch. 
The intra assay and inter assay coefficients of 
variation (CVs) for this standard were 6.01% 
and 3.76%, respectively.
Total urinary As. All urine samples 
were analyzed for total urinary As (uAs) in 
the Columbia University Trace Metals 
Core Laboratory by graphite furnace atomic 
absorption spectrometry (Nixon et al. 1991) 
using the AAnalyst 600 graphite furnace sys-
tem (PerkinElmer, Shelton, CT, USA). A 
method based on the Jaffe reaction was used 
to measure urinary creatinine concentrations 
(Slot 1965). Method and instrument preci-
sion was checked by running four different 
urine samples with known concentrations (to 
cover the whole linearity range of the stan-
dard curve) every day immediately after the 
instrument calibration with aqueous stan-
dards. A urine sample with an As concen-
tration in the middle of the linearity range 
was run after every 10 study samples. The 
intra assay and inter assay CVs based on this 
quality control sample were 3.9% and 5.6%, 
respectively. For duplicate study samples, the 
intra assay and inter assay CVs were 3.8% and 
5.1%, respectively.
Total blood As. We used a Perkin-Elmer 
Elan DRC II ICP-MS equipped with an AS 
93+ auto sampler to analyze whole blood sam-
ples for total blood As (bAs) concentration, 
as described previously (Hall et al. 2006). 
The intra assay and inter assay CVs were 3.2% 
and 5.7%, respectively, for quality control 
samples. For study samples, the intra assay 
and inter assay CVs were 2.1% and 4.9%, 
respectively.
Blood GSH and GSSG and plasma Cys 
and CySS. Whole blood GSH and GSSG 
and plasma Cys and CySS were assayed 
essentially as described by Jones et al. (1998). 
Blood was collected with a butter fly needle 
and syringe and then immediately transferred 
into Eppendorf tubes. For whole blood mea-
surements, the Eppendorf tubes contained 
5% perchloric acid, 0.1 M boric acid, and 
γ-glutamyl glutamate as an internal stan-
dard. For plasma measure ments, the tubes 
contained 0.53 g l-serine, 25 mg heparin, 
50 mg batho phenanthrolene, 300 mg iodo-
acetic acid, and 10 mL borate buffer stock 
(12.4 g boric acid, 19 g sodium tetra borate 
decahydrate, and 500 mL distilled water). The 
samples for plasma measure ments were centri-
fuged for 1 min, and 200 µL of supernatant 
was transferred into Eppendorf tubes con-
taining an equal volume of 10% perchloric 
acid and 0.2 M boric acid. For derivatization, 
plasma samples were centrifuged at 13,000 
rpm for 2 min, 300 µL of supernatant was 
transferred to a fresh tube, and the pH was 
adjusted to 9.0. After incubating for 20 min 
at room temperature, dansyl chloride was 
added, and samples were incubated at room 
temperature in the dark for 24 hr. The deriva-
tized samples were then stored at –80°C until 
delivered to Columbia University for analy-
sis. Free dansyl chloride was extracted from 
thawed samples with 500 µL chloroform, 
and then 20 µL of the sample was injected 
onto the HPLC. Separation was achieved 
using a Supelcosil LC-NH2 column (catalog 
no. 58338; Sigma Chemical Co., St. Louis, 
MO, USA). Initial solvent conditions were 
60% A (80% methanol, 20% water), 40% 
B (acetate-buffered methanol, pH 4.6) run 
at 1 mL/min for 10 min. A linear gradient 
to 20% A, 80% B was run during the 10- 
to 50-min period. From 50 to 52 min, the 
conditions were returned to 60% A, 40% B. 
Metabolites were detected using a Waters 474 
scanning fluorescence detector (Waters Corp., 
Milford, MA, USA), with 335 nm excitation 
and 515 nm emission. Within-assay CVs were 
all between 0.05 and 0.10, and inter assay CVs 
were between 0.11 and 0.18.
Plasma folate. Plasma folate was analyzed 
by radio protein-binding assay (SimulTRAC-S; 
MP Biomedicals, Orangeburg, NY, USA). To 
determine folate concentrations, we used folic 
acid as pteroyl glutamic acid for calibration, 
and its 125I-labeled analog as the tracer. The 
intra assay and inter assay CVs were 0.06 and 
0.14, respectively.
Calculation of the reduction potential. 
The reduction potential (Eh) of the thiol/
disulfide GSH/GSSG and Cys/CySS redox 
pairs (blood GSH Eh and plasma Cys Eh, 
respectively) were calculated using the 
Nernst equation: 
 Eh = Eo + RT/nF ln(acceptor/(donor)2, 
where Eo is the standard potential for the 
redox couple, R is the gas constant, T is the 
absolute temperature, n = 2 for the number of 
electrons transferred, and F is Faraday’s con-
stant (Jones et al. 2002). For GSH and GSSG, 
the equation simplifies to 
Eh (mV) = −264 + 30 log[(GSSG)/(GSH2)],
where (GSH) and (GSSG) are molar concen-
trations, and the Eo value assumes a physio-
logic pH of 7.4. A more positive Eh value 
indicates a more oxidized redox state.
Statistical methods. We calculated descrip-
tive statistics for characteristics of the study 
sample, As exposure variables (wAs, uAs, and 
bAs), and outcome variables (blood GSH 
and GSSG, plasma Cys and CySS), both for 
the total sample and by sex. Bivariate asso-
ciations were examined using scatter plots and 
Spearman’s correlation coefficients. To exam-
ine the bivariate associations between dichoto-
mous covariates and As exposure variables or 
continuous outcome variables we used t-tests 
or the non parametric Wilcoxon rank sum test.
We used linear regression models to fur-
ther examine the associations between As 
exposure variables, as continuous variables, 
and the outcome variables, with and with-
out adjustment for potential confounders. 
Age and sex were included in all covariate-
adjusted regression models. Other covariates 
considered for inclusion in the regression 
models were variables reported to be associ-
ated with the exposures or outcomes based on 
previous publications and/or variables associ-
ated with the exposure and outcome vari-
ables in the present study population. These 
variables included television ownership (as a 
surrogate for socio economic status), cigarette 
smoking, body mass index (BMI), urinary 
creatinine, and plasma folate. We adjusted for 
GSH laboratory batch (as a categorical vari-
able) in order to reduce extraneous variation 
in the outcome variables. We also calculated 
the change in R 2 between models for each 
outcome that included covariates only and 
corresponding models that included both the 
covariates and As exposure.
To facilitate comparisons among the dif-
ferent measures of exposure (wAs, uAs, and 
bAs), we report the estimated change in the 
mean value of blood GSH, blood GSH Eh, 
plasma CySS, and plasma Cys Eh associated 
with an interquartile range (IQR) increase 
in each exposure. For outcome variables that 
were natural log-transformed (blood GSSG 
and plasma Cys) we report the ratio of esti-
mated geometric means for an IQR change in 
As exposure.
To examine possible nonlinear relation-
ships, we also created quintiles of As exposure 
variables and computed covariate-adjusted 
mean values of the outcome variables for 
cate gories of As exposure; plots of quintile-
specific adjusted mean values were exam-
ined to determine if the association was 
approxi mately linear.
We ran separate linear regression models 
to examine the covariate-adjusted associa-
tions between As exposure and the outcome 
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variables stratified by sex or by folate status. 
We then used a Wald test to detect differ-
ences in the covariate-adjusted associations 
between As exposure and outcome variables 
by sex or by folate status. All analyses were 
performed using SAS (version 9.2; SAS 
Institute Inc., Cary, NC, USA); all statisti-
cal tests were two-sided with a significance 
level of 0.05.
Results
The general characteristics of the study sam-
ple are shown in Table 1. The median age 
was 42 years, approximately half of the study 
partici pants were female, and the median BMI 
was 19.7. wAs exposure ranged from 0.4 to 
700 µg/L; by design, nearly 80% of the par-
ticipants had wAs concentrations above the 
World Health Organization (WHO) standard 
of 10 µg/L for drinking water (WHO 2004). 
As we have observed previously (Gamble et al. 
2005), males and females differed on the fol-
lowing characteristics: Males a) had more 
years of formal education (median: males, 4; 
females, 1; p = 0.001); b) were more likely 
to report being ever-smokers (males, 69%; 
females, 5.7%; p < 0.0001); c) were more 
likely to have a BMI < 18.5 (males, 40.8%; 
females, 26.4%; p = 0.003); d) were more 
likely to have plasma folate concentrations 
< 9 nmol/L (males, 38.8%; females, 20.6%; 
p < 0.0001), which is indicative of marginal 
folate status; and e) were more likely to have 
total homo cysteine concentrations above 
the cut off for hyper homo cysteinemia of 
13 µmol/L (males, 25.5%; females, 7.2%; 
p = 0.0001). We observed other differences 
between the sexes that were specific to the 
present study sample: The males were older 
than the females (median: males, 44.0 years; 
females, 40.0 years; p = 0.001) and had 
higher bAs concentrations (median: males: 
12.3 µg/L; females, 10.3 µg/L; p = 0.009). 
Blood GSH Eh and plasma Cys Eh also dif-
fered significantly by sex; median blood 
GSH Eh values for females indicated a more 
oxidized intra cellular redox state compared 
with males (median: males, –203.2; females, 
–197.4; p < 0.0001), whereas median plasma 
Cys Eh values for males indicated a more 
oxidized extra cellular redox state compared 
with females (median: males, –46.1; females, 
–49.4; p = 0.03).
Several covariates were associated with As 
exposure variables and/or outcome variables. 
All three measures of As exposure were nega-
tively associated with BMI (see Supplemental 
Material, Table S1). Plasma folate was posi-
tively associated with blood GSSG. Age, BMI, 
and plasma folate were all positively associ-
ated with plasma CySS; age was also nega-
tively associated with plasma Cys. We also 
observed differences by sex, smoking, and tele-
vision owner ship (see Supplemental Material, 
Table S2). Males had higher blood GSH and 
lower plasma Cys and blood GSH Eh (indi-
cating a less oxidized redox state) than did 
females. Ever-smokers also had significantly 
higher bAs than never-smokers. Contrary to 
expectation, ever-smokers had higher blood 
GSH concentrations and lower blood GSH 
Eh than never-smokers. However, most smok-
ers were males, and after stratification by sex, 
there were no statistically significant difference 
in blood GSH and blood GSH Eh by smok-
ing status (data not shown). Participants who 
owned a tele vision had lower wAs and uAs 
concentrations and higher blood GSH, blood 
GSSG, and plasma CySS concentrations than 
participants who did not own a television. 
In the models in which we computed 
covariate-adjusted mean values of the outcome 
variables for each quintile of As exposure, 
we did not detect any substantial departures 
from linearity (data not shown). In models 
using continuous As exposure variables, 
all three markers of As exposure were nega-
tively associated with blood GSH [estimated 
changes in mean blood GSH associated with 
an IQR increase in exposure from covariate-
adjusted models were –25.4 µmol/L (95% CI: 
–45.3, –5.31), p = 0.01 for wAs; –54.0 µmol/L 
(95% CI: –90.8, –17.2), p = 0.004 for uAs; 
and –33.4 µmol/L (95% CI: –62.8, –3.9), 
p = 0.03 for bAs] and positively—but not 
always significantly—associated with blood 
GSH Eh [change in the estimated mean with 
an IQR increase in exposure from covariate-
adjusted models: 1.19 (95% CI: –0.25, 2.62), 
p = 0.10 for wAs; 2.72 (95% CI: 0.10, 5.35), 
p = 0.04 for uAs, and 1.73 (95% CI: –0.37, 
3.83), p = 0.11 for bAs] (Table 2). The change 
in R2 values for blood GSH models were 
1.3% for wAs, 1.8% for uAs, and 1.1% for 
bAs; these values can be interpreted as the pro-
portion of the variance in blood GSH that is 
accounted for by each As exposure variable 
after controlling for covariates. We observed 
no significant associations between As exposure 
and blood GSSG concentrations (Table 2). In 
unadjusted models, wAs and bAs were signifi-
cantly negatively associated with plasma Cys. 
However, associations were positive (although 
not statistically significant) after adjustment 
for covariates. All three markers of As exposure 
were negatively associated with plasma CySS 
in both covariate-unadjusted and covariate-
adjusted models [estimated changes in mean 
plasma CySS associated with an IQR increase 
in exposure from covariate-adjusted models 
were –3.00 µmol/L (95% CI: –4.61, –1.40; 
p  = 0.0002) for wAs; –3.56 µmol/L 
(95% CI: –6.47, –0.66; p = 0.02) for uAs, 
and –3.09 µmol/L (95% CI: –5.40, –0.79; 
p = 0.009) for bAs] and negatively associ-
ated with plasma Cys Eh [estimated changes 
in mean plasma Cys Eh associated with an 
IQR increase in exposure from covariate-
adjusted models were –2.05 µmol/L (95% CI: 
–3.89, –0.21; p = 0.03) for wAs; –4.04 µmol/L 
(95% CI: –7.34, –0.74; p = 0.02) for uAs; 
and –2.01 µmol/L (95% CI: –4.65, 0.64; 
p = 0.14) for bAs], indicating that As expo-
sure is associated with a more reduced extra-
cellular environment. The change in R2 values 
for plasma CySS models with adjustment for 
As exposure (compared with covariates alone) 
were 2.7% for wAs, 1.2% for uAs, and 1.4% 
Table 1. Characteristics of the study sample, for all participants and by sex.a
Characteristic Total sample (n = 378) Females (n = 194) Males (n = 184)
Age (years) 42.0 (13.0) 40.0 (13.0) 44.0 (14.0)
Education (years) 3.0 (5.0) 1.0 (5.0) 4.0 (6.0)
BMI (kg/m2) 19.7 (5.0) 20.7 (5.0) 19.0 (4.2)
BMI < 18.5 (%) 33.4 26.4 40.8
Ever-smoker (%) 36.5 5.7 69.0
Ever betel nut use (%) 42.6 41.2 44.0
Television ownership (%) 58.2 57.2 59.2
wAs (µg/L) 114.0 (190.3) 113.1 (186.9) 114.1 (215.2)
wAs > 10 µg/L (%) 79.9 80.4 79.4
wAs > 50 µg/L (%) 68.3 68.6 67.9
uAs (µg/L) 122.5 (223.0) 119.0 (217.0) 126.0 (218.0)
Urinary creatinine (mg/dL) 40.3 (57.0) 36.2 (49.8) 44.0 (57.1)
uAs/g creatinine 329.5 (454.0) 360.0 (465.0) 307.5 (392.0)
bAs (µg/L) 10.9 (13.3) 10.3 (12.4) 12.3 (14.3)
Plasma folate (nmol/L) 11.1 (6.5) 12.5 (6.9) 9.7 (5.1)
Folate deficient, < 9 nmol/L (%) 29.4 20.6 38.8
Homocysteine (µmol/L) 9.0 (4.3) 7.7 (3.5) 10.7 (5.1)
Hyperhomocysteinemia, > 13 µmol/L (%) 16.1 7.2 25.5
Blood GSH (µmol/L) 494.6 (227.3) 436.6 (212.0) 529.7 (209.7)
Blood GSSG (µmol/L) 34.3 (23.4) 34.5 (20.6) 33.9 (25.8)
Blood GSH Eh –199.9 (14.3) –197.4 (12.4) –203.2 (12.3)
Plasma Cys (µmol/L) 3.2 (2.8) 3.5 (2.5) 2.9 (2.9)
Plasma CySS (µmol/L) 55.5 (19.0) 53.6 (19.7) 56.2 (19.0)
Plasma Cys Eh –48.5 (22.6) –49.4 (19.3) –46.1 (24.0)
Abbreviations: bAs, blood As; Cys, cysteine; CySS, cystine; Eh, reduction potential; GSH, glutathione; GSSG, glutathione 
disulfide; uAs, urinary As; wAs, water As. 
aValues are median (interquartile range) unless otherwise noted.
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for bAs. Given that males and females in this 
study population differed substantially on 
several charac teristics, all regression models 
were also run stratified by sex; the directions 
of associa tions in males and females were the 
same as in the overall sample, but in some cases 
did not reach statistical significance because 
of the smaller sample sizes (data not shown). 
We also examined the possibility that asso-
ciations might differ by folate status (deficient: 
< 9 nmol/L, sufficient: ≥ 9 nmol/L) given 
the influence of folate on As methylation 
(Gamble et al. 2006). We observed no statisti-
cally significant differences in the associations 
between blood As and any of the outcome 
variables by folate status (see Supplemental 
Material, Table S3).
Discussion
In this cross-sectional study of Bangladeshi 
adults chronically exposed to a wide range 
of As concentrations in drinking water, we 
observed that three different measures of As 
exposure (wAs, uAs, and bAs) were all nega-
tively associated with blood GSH. Contrary 
to our primary a priori hypothesis, As 
exposure was not positively associated with 
blood GSSG, the oxidized form of GSH. 
Also, contrary to our secondary hypotheses, 
we observed no association between As and 
plasma Cys, and we saw a negative—rather 
than positive—association with plasma CySS.
To our knowledge, only one other 
population-based study has examined the 
association between As exposure and GSH 
concentrations. Xu et al. (2008) recruited 
208 participants with high wAs exposure 
(90 µg/L or 160 µg/L) and 59 participants 
with low wAs exposure (20 µg/L) from 
three villages in Inner Mongolia, China. 
Participants with high wAs exposure had 
significantly lower blood total non-protein 
sulfhydryl concentrations (NPSH, primarily 
GSH) than those with low wAs exposure. 
Xu et al. (2008) did not report findings for 
blood GSSG.
Our findings and those of Xu et al. (2008) 
are generally consistent with rodent studies 
showing that high-dose As exposure depletes 
GSH (Maiti and Chatterjee 2001; Santra 
et al. 2000). Santra et al. (2000) reported that 
mice administered As through drinking water 
(3,200 µg/L) ad libitum had elevated hepatic 
GSH after 2 months and decreased hepatic 
GSH after 4 months compared with mice 
adminis tered As-free water. In male Wistar 
rats, Maiti and Chatterjee (2001) found that 
a single intra peritoneal dose of sodium arse-
nite (15,860 µg/kg body weight) resulted in a 
signifi cant reduction in hepatic GSH.
Despite the evidence suggesting that As 
exposure is associated with reductions in 
GSH, the question of whether or not chronic 
exposure—at doses relevant to human popula-
tions—results in oxidative stress per se remains 
unclear. Some in vitro and animal model 
studies have reported that As exposure led to 
an increase in the production of ROS and a 
decline in GSH (Flora et al. 2012; Thompson 
and Franklin 2010; Zhang et al. 2011). 
However, these studies used high doses of 
As, doses that are often not relevant to actual 
human exposures. For example, Flora et al. 
(2012) adminis tered an As dose of 50 ppm 
in drinking water (~ 50,000 µg/L) to mice. 
We would not expect very high doses to pro-
duce the same effects as the doses to which 
our study participants were exposed (median, 
114 µg/L). In addition, there are well known 
species differences in both As metabolism 
and susceptibility to As-induced health effects 
(Drobná et al. 2010).
The negative associations between As 
exposure and blood GSH and plasma CySS, 
although statistically significant, accounted 
for a small proportion of the estimated vari-
ance in blood GSH (1.1–1.8%) and plasma 
CySS (1.2–2.7%). Our findings, as well as the 
inconsistent findings from other population-
based studies examining associations between 
Table 2. Covariate-unadjusted and -adjusted effect size estimates for associations between measures of As exposure and GSH, GSSG, Cys, and CySS.
wAs (µg/L) uAs (µg/L) bAs (µg/L)
Unadjusted Adjusteda Unadjusted Adjustedb Unadjusted Adjusteda
Blood GSH (µmol/L)
Mean change (95% CI)c –33.8 (–49.3, –18.0) –25.4 (–45,3, –5.31) –59.6 (–84.0, –35.3) –54.0 (–90.8, –17.2) –46.6 (–72.3, –21.1) –33.4 (–62.8, –3.9)
p-Value < 0.0001 0.01 < 0.0001 0.004 0.0004 0.03
R 2 4.6 23.5 5.8 24.8 3.3 23.3
∆R 2 1.3 1.8 1.1
Blood GSSG (µmol/L)
Mean ratio (95% CI)d 1.00 (0.95, 1.04) 0.98 (0.95, 1.02) 1.07 (0.99, 1.14) 0.95 (0.88, 1.05) 0.99 (0.92, 1.06) 0.98 (0.91, 1.04)
p-Value 0.88 0.42 0.07 0.31 0.63 0.43
R 2 0.0 47.8 0.8 48.0 0.06 47.8
∆R 2 0.1 0.2 0.1
Blood GSH Eh (mV)e
Mean change (95% CI)c 1.92 (0.74, 3.11) 1.19 (–0.25, 2.62) 4.51 (2.67, 6.35) 2.72 (0.10, 5.35) 2.64 (0.70, 4.58) 1.73 (–0.37, 3.83)
p-Value 0.002 0.10 < 0.0001 0.04 0.008 0.11
R 2 2.6 31.1 5.8 32.2 1.9 31.1
∆R 2 0.5 0.8 0.5
Plasma Cys (µmol/L)
Mean ratio (95% CI)d 0.93 (0.88, 0.98) 1.06 (0.98, 1.14) 0.98 (0.89, 1.09) 1.12 (0.99, 1.28) 0.90 (0.81, 0.99) 1.05 (0.95, 1.16)
p-Value 0.01 0.14 0.73 0.06 0.03 0.34
R 2 1.7 39.4 0.0 40.6 1.3 39.2
∆R 2 0.3 0.6 0.1
Plasma CySS (µmol/L)
Mean change (95% CI)c –2.94 (–4.19, –1.69) –3.00 (–4.61, –1.40) –1.78 (–3.80, 0.25) –3.56 (–6.47, –0.66) –4.11 (–6.17, –2.06) –3.09 (–5.40, –0.79)
p-Value < 0.0001 0.0002 0.08 0.02 0.0001 0.009
R 2 5.3 29.8 0.8 28.8 4.0 28.5
∆R 2 2.7 1.2 1.4
Plasma Cys Eh (mV)f
Mean change (95% CI)c 1.38 (–0.21,2.98) –2.05 (–3.89, –0.21) –0.007 (–2.51, 2.49) –4.04 (–7.34, –0.74) 1.90 (–0.67, 4.48) –2.01 (–4.65, 0.64)
p-Value 0.09 0.03 0.99 0.02 0.15 0.14
R 2 0.8 38.3 0.0 39.1 0.6 37.8
∆R 2 0.9 1.0 0.4
Abbreviations: bAs, blood As; Cys, cysteine; CySS, cystine; Eh, reduction potential; GSH, glutathione; GSSG, glutathione disulfide; uAs, urinary As; wAs, water As. 
aAdjusted for log-transformed age, sex, television ownership (yes/no), smoking (ever/never), log-transformed BMI and plasma folate, and GSH/Cys laboratory batch.  bAlso adjusted for 
log urinary creatinine. cRepresents the mean change in the outcome for a change in the exposure from the 25th to the 75th percentile. dRepresents the ratio of the geometric mean in 
the outcome for a change in the exposure from the 25th to the 75th percentile. eReduction potential of the GSH/GSSG redox pair. fReduction potential of the Cys/CySS redox pair.
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As exposure and blood markers of oxidative 
damage (Burgess et al. 2007; Engström et al. 
2010a, 2010b; Pi et al. 2002), raise the pos-
sibility that, despite reductions in GSH, As 
may not induce substantial, sustained oxida-
tive stress that is measurable in blood using 
these biomarkers at environmentally relevant 
As exposures. We cannot determine from 
this study what the functional effects of the 
observed reduction in blood GSH might be; 
however, alterations in GSH have been linked 
to the development and/or progression of 
numerous diseases (Ballatori et al. 2009).
Research by Waalkes and colleagues sug-
gests that human cells can adapt to low-level 
As exposure through alterations in the one-
carbon metabolic pathway (Coppin et al. 
2008). Exposure of human prostate epithelial 
RWPE-1 cells (which do not methylate As) 
to 5 µM sodium arsenite for up to 16 weeks 
resulted in reductions in SAM and increases 
in S-adenosyl homocysteine and homo-
cysteine. In addition, As exposure increased 
the expression of cystathionine β-synthase, 
the enzyme that catalyzes the first step in 
GSH production via the trans sulfuration 
pathway, and increased cellular reduced GSH 
by 5-fold (Coppin et al. 2008). Collectively, 
these findings suggest that in RWPE-1 cells, 
low-level As exposure increases shunting of 
homo cysteine to the trans sulfuration path-
way to increase GSH production, resulting 
in decreased remethylation of homo cysteine 
to SAM. Exposure to As also resulted in 
increased expression of the ATP-binding cas-
sette protein C1 (ABBC1) and increased efflux 
of As from RWPE-1cells (Coppin et al. 2008). 
Given that ABBC1 encodes a protein involved 
in the efflux of a triglutathione-arsenical 
complex (Leslie et al. 2004), the findings of 
Coppin et al. (2008) suggest that As may exert 
a strong influence on GSH concentrations 
through this mechanism.
We observed a negative association 
between As exposure and blood GSH but no 
association with blood GSSG, a finding that 
is most consistent with the hypothesis that 
As may reduce GSH through binding and 
irreversible loss in bile and/or possibly in urine 
(Kala et al. 2004). This finding also suggests 
that other proposed As-mediated mecha-
nisms [specifically, GSH depletion during the 
detoxi fi cation of ROS; GSH depletion dur-
ing the reduction of AsV to AsIII (Scott et al. 
1993); or As-mediated glutathione reductase 
inhibition resulting in reduced regeneration of 
GSH from GSSG (Styblo et al. 1997)] did not 
strongly influence GSH status in our chroni-
cally exposed Bangladeshi study population. 
Associations between the IQR increases in 
wAs and bAs and the outcomes were gener-
ally quite similar (Table 2). For blood GSH, 
blood GSH Eh, plasma CySS, and plasma Cys 
Eh, the magnitudes of the associations were 
somewhat stronger for an IQR increase in uAs 
compared with IQR increases in wAs and bAs.
A secondary hypothesis of the pres-
ent study was that As would be negatively 
associated with Cys because Cys is required 
for GSH synthesis. However, our findings 
showed a positive but not statistically sig-
nificant association with plasma Cys and a 
negative association with CySS. The lack of 
a statistically significant association with Cys 
may potentially be explained by the fact that 
free Cys is extremely unstable extra cellularly 
and rapidly oxidizes to CySS (Lu 2009). In 
fact, one of the functions of GSH is to serve as 
a storage form of Cys through the γ-glutamyl 
cycle (Meister and Anderson 1983). Given 
that Cys is constantly in flux, the measure-
ment of plasma Cys may reflect one snap-
shot of Cys concentrations rather than the 
overall Cys status of an individual. In a study 
designed to examine the long-term stability 
of blood glutathione and cyst(e)ine (i.e., cys-
teine + cystine) measurements, Richie et al. 
(1996) reported low inter individual variability 
in cyst(e)ine, which suggests that measures of 
Cys and/or CySS in whole blood or plasma 
may not be as useful as a biomarker of long-
term cyst(e)ine status.
A number of factors influence GSH con-
centrations (including age, smoking, physi-
cal activity, and diet), and an individual’s 
response to As might depend on their back-
ground level of oxidative stress. A mathe-
matical model of one-carbon metabolism 
developed by Reed et al. (2008) predicted that 
changes in GSH and Cys with oxidative stress 
depend on the severity of the oxidative stress. 
For example, with moderate over all oxidative 
stress, blood and cytosolic GSH and cyto-
solic Cys increase while blood Cys decreases. 
This initial increase in GSH results from the 
stimulation of enzymes involved in GSH syn-
thesis. With severe oxidative stress, values of 
all four metabolites decrease sharply (Reed 
et al. 2008). In our statistical analysis, we 
did not find evidence of non linear relation-
ships between As exposure and the outcome 
variables (data not shown). In addition, we 
controlled for several potential confounding 
factors. However, we were unable to adjust for 
physical activity, a variable previously shown 
to be associated with GSH (Rundle et al. 
2005), and uncontrolled confounding by this 
or other unmeasured factors is possible.
Conclusions
We observed that As exposure was negatively 
associated with blood GSH and plasma CySS 
in a population chronically exposed to a 
wide range of As concentrations in drinking 
water. These findings, and the lack of asso-
ciation between As exposure and blood GSSG 
or plasma Cys, suggest that As may exert its 
greatest influence on GSH through binding 
and irreversible loss in bile and/or possibly in 
urine. Our findings do not lend strong sup-
port to the hypothesis that As induces levels 
of oxidative stress that are measurable in blood 
using these biomarkers and at these environ-
mentally relevant exposures. However, our 
findings cannot rule out the possibility of 
As-induced oxidative stress in tissue or cellu lar 
compartments that we were unable to measure 
in healthy human volunteers.
correction
In the manuscript originally published 
online, Abu B. Siddique’s name was listed 
incorrectly. It has been corrected here.
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